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It has been proposed that schizophrenia results from an environmental insult in genetically predisposed individuals. Environmental
factors capable of modulating transcriptional activity and their carriers could link the genetic and environmental components of schizo-
phrenia. Among these is transthyretin (TTR), a major carrier of thyroid hormones and retinol-binding protein (RBP). Retinoids and
thyroid hormones regulate the expression of several genes, both during development and in the adult brain. Decreased TTR levels have
been reported in the cerebrospinal fluid of patients with depression and Alzheimer’s disease, and the absence of TTR influences behavior
in mice. DNA variants capable of altering TTR ability to carry its ligands, either due to reduced transcription of the gene or to structural
modifications of the protein, may influence development of the central nervous system and behavior. In the present study we searched for
variants in the regulatory and coding regions of the TTR gene, and measured circulating levels of TTR and RBP. We found a novel single
nucleotide polymorphism (SNP), ss46566417, 18 bp upstream of exon 4. Neither this SNP nor the previously described rs1800458 were
found associated with schizophrenia. In addition, serum TTR and RBP levels did not differ between mentally healthy and schizophrenic
individuals. In conclusion, our data does not support an involvement of the TTR gene in the pathophysiology of schizophrenia.
 2006 Elsevier Ltd. All rights reserved.
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Schizophrenia is a complex neurodevelopment disorder
(Beckmann, 1999). Epidemiological studies indicate an0022-3956/$ - see front matter  2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.jpsychires.2006.04.003
* Corresponding author. Tel.: +351 253604817; fax: +351 253604809.
E-mail address: japalha@ecsaude.uminho.pt (J.A. Palha).increased risk for developing schizophrenia in relatives of
probands with the disease (Gottesman, 1991), suggesting
a genetic predisposition. However, monozygotic twins are
frequently phenotypically discordant, which implies that
environmental factors must play a role in the disease etio-
logy (Tsuang et al., 2001).
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mental factors proposed to be altered in schizophrenia
(Goodman, 1998; Palha and Goodman, 2005). It is widely
recognized that thyroid hormones and retinoids are essen-
tial for the normal development of the central nervous sys-
tem, and that lack of adequate levels during pregnancy
leads to several neurological defects (Lane and Bailey,
2005; Luo et al., 2004; Morreale de Escobar, 2003; Morre-
ale de Escobar et al., 2004; Wietrzych et al., 2005). Thyroid
hormones and retinoids act as modulators of the expres-
sion of several genes through the binding of retinoic acid
and triiodothronine to the corresponding nuclear recep-
tors. Interestingly, evidence of altered retinoid and thyroid
hormone metabolisms in schizophrenic patients is arising
from studies in postmortem brains, in which RARa and
myelin-basic protein, genes whose expression is regulated
by thyroid hormones and retinoids, were found to have
altered expression (Hakak et al., 2001; Rioux and Arnold,
2005).
By influencing ligand availability, carriers of thyroid hor-
mones and retinoids indirectly regulate the transcription of
several genes. Among the modulators of thyroid hormone
and retinoid availability is transthyretin (TTR), a major
carrier of thyroxine and retinol [through association with
(RBP)], both in serum and in cerebrospinal fluid (CSF)
(Palha, 2002). TTR has been implicated in behavior:
decreased TTR CSF levels were found in patients with
depression (Sullivan et al., 1999) and with Alzheimer’s dis-
ease (Serot et al., 1997). Whether this decrease is the result
or a consequence of the disease or whether it is caused by
medication is still unclear. Supporting that both processes
might be implicated in behavior are the observations that
TTR-null mice (Palha 2002) present increased motor activ-
ity in behavior tests that address anxiety-like and depres-
sion-like behaviors (Sousa et al., 2004), and that clozapine
treatment induces TTR expression in the brain (Chen and
Chen, 2005).
The TTR gene is a single copy gene, on 18q12.1, com-
posed of four exons (Tsuzuki et al., 1985) that encodes a
14 kDa subunit which assembles as a tetramer (Blake
et al., 1978). Whereas plasma TTR originates primarily
from the liver, CSF TTR is mainly produced and secreted
from the choroid plexus, where it represents about 20% of
the total protein synthesis (Aldred et al., 1995). The obser-
vation that homologues of the TTR protein can be found
in a wide range of species (Eneqvist et al., 2003) and that
its synthesis starts early during embryonic development
(Larsen and DeLallo, 1989), suggests a relevant role for
TTR in development.
These observations, prompted us to investigate the TTR
gene as a candidate gene in schizophrenia. In the present
study we searched for variants in the regulatory and coding
regions of the TTR gene, and association between the poly-
morphisms detected and schizophrenia were analyzed in
three different samples. We also investigated serum TTR
and RBP levels in schizophrenic and in mentally healthy
individuals.2. Materials and methods
2.1. Samples
Two case–control samples were used: one from Portu-
gal-mainland and a second from Brazil. A total of 244
unrelated schizophrenic patients (175 males and 69
females) and 210 controls (131 males and 79 females) were
recruited from the north and center of Portugal-mainland.
The Brazilian sample consisted of 69 cases and 85 controls,
all unrelated males living in the area of Porto Alegre. A
third, independent sample composed of 73 patients (47
males and 26 females) and their parents from the Azorean
Islands (Portugal), was used for family-based association
analysis. All subjects were of European ancestry. All par-
ticipants gave informed consent for genetic studies and
ethic committees of the institutions involved approved
the study.
All patients from Portugal-mainland and Azorean
Islands, as well as 45% of Portugal-mainland controls
and 67% of the Azorean parents were evaluated using the
Diagnostic Instrument for Genetic Studies (DIGS) (Nurn-
berger et al., 1994), a semi-structured interview that
assesses the criteria for schizophrenia and other psychiatric
diseases. The diagnosis was made based on the Diagnostic
and Statistical Manual of Mental Disorders, review of the
third edition (DSM-IIIR, 1985) (American Psychiatric
Association, 1987). All Brazilian patients were classified
using the Operational Checklist for Psychotic Disorders
(OPCRIT) (McGuffin and Farmer, 2001). No psychologi-
cal assessment interviews have been conducted in the
remaining Portuguese mainland controls (students and tis-
sue donors) or Azorean parents, or in any of the Brazilian
controls (blood donors).2.2. Polymorphism screening
Using single strand conformational polymorphism
(SSCP) analysis, a sub-sample of 60 patients from the Por-
tuguese mainland was used for screening variants in all
four exons and adjacent splicing sites, as well as in the pro-
moter and the 3 0 untranslated regions. For this analysis the
PCR products were subjected to electrophoresis on a non-
denaturing polyacrylamide gel under two temperature
conditions: 4 C and 25 C. After completion of the electro-
phoresis, band patterns were visualized with silver staining,
using standard protocols. PCR products from subjects dis-
playing altered band patterns in the SSCP analyses were
sequenced in both directions. The sequencing reactions
were performed using the BigDye Sequencing Kit 3.1 and
run on the 3700 sequencer, both from Applied Biosystems
(Foster City, CA).
The TTR sequence was obtained from the GenBank
Data Libraries (Accession No. M11844) and the Primer3
program (Rozen and Skaletsky, 2000) was used for primer
design. Primer sequences are available upon request.
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Two single nucleotide polymorphisms (SNP) (rs1800458
on exon 2 and ss46566417 on intron 3) were detected
(Fig. 1). These two SNPs were further typed for association
in the complete samples described above.
Detection of rs1800458 and ss46566417 was based upon
analysis of primer extension products generated from pre-
viously amplified genomic DNA, using a chip-based
MALDI-TOF mass spectrometry platform (SEQUENOM
Inc., San Diego, CA). PCR primers with a universal (10 bp)
sequence at the 5 0 end (5 0-ACGTTGGATG-3 0) and the
extension primer were created using the MassARRAY
Assay Design 2.0 software (SEQUENOM), following man-
ufacturer’s instructions. For the MALDI-TOF analysis,
aliquots of the samples were spotted onto a SpectroCHIP
(SEQUENOM). Mass spectra were generated by the Mass-
ARRAY spectrometer (SEQUENOM). Genotypes were
automatically determined using the SpectroTYPER soft-
ware (SEQUENOM). In some cases genotyping of
rs1800458 was repeated using PCR-based restriction frag-
ment length polymorphism assay. The same PCR product
used for the SSCP analysis was digested with the endonu-
clease Cfr 10I (Fermentas, Vilnius, Lithuania). The
digested reactions were resolved by electrophoresis on 3%
agarose gels.
2.4. Measurement of TTR and RBP serum levels
Twenty-six schizophrenic patients (16 males and 10
females) and 54 controls (25 males and 29 females) from
Portugal-mainland as well as 27 schizophrenic patients
(15 males and 12 females) from the Azorean Islands were
used to measure the serum levels of TTR, RBP, and albu-
min. Serum TTR, RBP, and albumin were determined by
radial-immunodiffusion in accordance to the manufac-
turer’s instructions (The Binding Site Limited, Birming-
ham, UK).
2.5. Statistical analysis
The genotype and allele frequencies were compared
between cases and controls using a standard v2 test, calcu-Fig. 1. Genomic structure of human TTR gene and locations of the two SN
represent untranslated regions. Locations of initiation (ATG) and stop (TGA
numbers identify the SNPs according with the dbSNP database of NCBI (httlated by SPSS (version 13.0). Hardy–Weinberg equilibrium
(HWE) was assessed in the same way.
To analyze the results of the family-based association
study (Azorean sample), a transmission disequilibrium test
(TDT) was performed, using TRANSMIT version 2.5.4
(Clayton, 1999).
Student’s t test was used to compare ages and protein
serum levels between patients and controls. Association
between serum TTR, RBP and albumin levels and their
correlation with age was analyzed by linear regression.
These last two analyses were also performed with SPSS.
For all tests, the results were considered significant when
the P-value was less than 5%.
3. Results
3.1. Association study
In the 60 patients screened for variants we detected the
presence of two SNPs: the previously described rs1800458
on exon 2 and the novel ss46566417, 18 bp upstream from
exon 4 (Fig. 1). The novel SNP has been submitted to the
NCBI SNP database (http://www.ncbi.nlm.nih.gov/SNP/).
HWE was verified for all tested samples, showing no
deviation for either SNP analyzed (Table 1). Table 1 sum-
marizes the genotyping results for the two SNPs. No signif-
icant differences between cases and controls were detected
in genotype or allele frequencies, either in the Portuguese
mainland or in the Brazilian samples. The lack of associa-
tion was confirmed in the Azorean sample, since the TDT
revealed no excess of transmission from parents to off-
spring (Table 2).
3.2. TTR, RBP and albumin serum levels
Serum levels of TTR, RBP and albumin did not differ
between schizophrenic and mentally healthy individuals,
whether male or female. There were no statistical differ-
ences of TTR, RBP or albumin serum levels between the
analyzed Portuguese mainland and Azorean patients.
Therefore these values are presented together in Table 3.
Distribution of age in the sample used was not well
matched between patients and controls (Table 3). How-Ps analyzed. Black boxes represent protein-coding regions, white boxes
) codons and sizes of introns and exons are also provided. The rs and ss
p://www.ncbi.nlm.nih.gov/SNP/).
Table 1
Case–control analyses for the two SNPs studied
Origin SNP (phenotype) Genotype (frequencies) P-value HWE
Portugal mainland rs1800458 GG GA AA
Cases (n = 163) 0.914 0.086 0.000 0.496 0.567
Controls (n = 161) 0.888 0.106 0.006 0.533
ss46566417 GG GC CC
Cases (n = 244) 0.906 0.094 0.000 0.513 0.440
Controls (n = 209) 0.890 0.105 0.005 0.691
Brazil rs1800458 GG GA AA
Cases (n = 69) 0.855 0.145 0.000 0.617 0.516
Controls (n = 85) 0.882 0.118 0.000 0.564
ss46566417 GG GC CC
Cases (n = 69) 0.928 0.072 0.000 0.964 0.755
Controls (n = 85) 0.929 0.071 0.000 0.736
Represented are the genotype frequencies, P-values and HWE values.
Table 2
Individual SNP analysis by TRANSMIT
SNPs Major > minor allele (frequencya) v2 (df = 1) P-value
rs1800458 G > A (0.034) 0.517 0.472
ss46566417 G > C (0.045) 0.077 0.782
a Frequency of the minor allele, produced by the TRANSMIT program.
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of TTR, RBP and albumin, as verified by linear regression
analysis (P-value = 0.176 for TTR, P-value = 0.330 for
RBP and P-value = 0.736 for albumin). As expected,
TTR and RBP levels were positively correlated, when ana-
lyzed by linear regression (P < 0.0005).
4. Discussion
In the present study we describe a novel TTR polymor-
phism, ss46566417 with an allele frequency of 0.048 in Cau-
casians [0.052 (47/906) in Portuguese from mainland, 0.048
(14/292) in Azorean, and 0.036 (11/308) in Brazilian]. This
novel polymorphism does not change the amino-acid
sequence of the protein, since it is localized on intron 3,
but might interfere with transcription given its close prox-
imity to a splicing site. We also detected the SNP rs1800458
at an allele frequency (0.059) similar to that previously
described in the Caucasian population (Jacobson et al.,
1995). Neither of these two SNPs was found associatedTable 3




Age 36.6 ± 15.0 29.7 ± 6.8 0.0
TTR (mg/L) 296.9 ± 49.4 295.4 ± 34.6 0.8
RBP (mg/L) 67.8 ± 16.3 65.4 ± 9.9 0.4
Albumin (g/L) 42.8 ± 5.6 43.9 ± 5.8 0.4
Data represented as means ± SD.with schizophrenia. While the present study, as many oth-
ers, failed to identify genetic variants that predispose to
schizophrenia, recent studies in brains from schizophrenic
patients have shown altered expression of several genes
(Hakak et al., 2001; Mirnics et al., 2000). Such alterations
might result from variants in the regulatory regions of the
genes but also from inadequate availability of transcription
modulators such as hormones and vitamins (Palha and
Goodman, in press). For these reasons, and even though
we failed to detect association of the TTR polymorphisms
with schizophrenia, in these two populations, we investi-
gated the circulating levels of TTR and also of RBP. Serum
levels of RBP did not differ between schizophrenic and
mentally healthy individuals. Being the only plasma carrier
for retinol, RBP is measured as a surrogate marker of ret-
inol in the circulation (de Pee and Dary, 2002). Therefore,
our data suggest that serum retinoid status is not altered in
patients diagnosed with schizophrenia, since retinol is the
most common form of retinoids in circulation. This is,
however, in contrast with another study in which the serum
levels of RBP and other inflammatory acute phase proteins
such as albumin were found decreased in the serum of Chi-
nese schizophrenic patients from Singapore (Wong et al.,
1996). Given that our patient sample showed normal albu-
min serum levels, and since RBP is a useful marker of pro-
tein malnutrition (de Pee and Dary, 2002) and of
inflammatory acute phase response (Fleck, 1989), it is pos-
sible that the values observed in that study might reflect avalue Females P-value
Cases Controls
22 29
28 42.2 ± 11.4 31.6 ± 9.9 0.001
98 277.0 ± 51.1 284.3 ± 49.5 0.610
95 64.9 ± 13.9 61.8 ± 13.4 0.427
73 41.0 ± 4.4 41.2 ± 4.9 0.906
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While we found no changes in RBP circulating levels in our
patient population, search for RBP variants should be
investigated since these could impair the ability to carry
retinol and/or to bind to TTR.
Ours is the first report on serum levels of TTR and we
found no differences between schizophrenic and control
individuals. It should be noted that serum TTR levels do
not necessarily reflect CSF levels since the first is mainly
derived form the liver while the latter is primarily synthe-
sized and secreted from the choroid plexus (Aldred et al.,
1995). In fact, TTR expression has been described as differ-
entially regulated in the liver and in the choroid plexus
(Dickson et al., 1986); probably due to the presence of tis-
sue specific transcription factors (Costa et al., 1990).
Recent interest on the possible decrease of CSF TTR dur-
ing aging has been raised mainly in the context of Alzhei-
mer’s disease, since TTR is also able to bind the
Alzheimer b peptide (Carro et al., 2005). It would therefore
be interesting to measure CSF TTR levels in patients,
where available, to extend a single study in which CSF
TTR levels were reported normal in patients with schizo-
phrenia (Bock, 1978). All together the data obtained to
date does not support the involvement of TTR in the path-
ophysiology of schizophrenia. However, it is important to
investigate whether TTR polymorphisms are related to
any particular symptom or response to medication, or
whether the levels of TTR ligands, rather than TTR itself,
are involved in the etiology of schizophrenia.
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